- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04733651
Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19
February 2, 2021 updated by: Dr. Pradip Gyanwali,MD, Nepal Health Research Council
A Randomized, Open-labelled and Controlled Clinical Trial to Investigate the Clinical Efficacy of Isoquercetin in the Treatment of Mild-to-moderate Hospitalised COVID-19 Patients
The purpose of this study is to investigate the clinical efficacy of Isoquercetin in preventing disease progression and symptoms improvement in mild-to-moderate hospitalised COVID-19 patients.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This is an open-labelled, randomized and multi-centre clinical trial in subjects with RT-PCR confirmed SARS-CoV-2 infection with mild-to-moderate symptoms, and who are currently admitted to the hospital for diagnosis of COVID-19.
The study has two arms: hospital standard COVID-19 care (Control group) and hospital standard COVID-19 care + Isoquercetin (Isoquercetin group).
The recruited subjects will be placed into either group by an electronic randomization process.
Patients in the Isoquercetin group will receive a daily dose of 1000 mg Isoquercetin as 4 x 250 mg Isoquercetin capsules as add-on therapy in addition to the hospital standard COVID-19 care.
The Isoquercetin treatment will continue for 28 days.
Study Type
Interventional
Enrollment (Anticipated)
250
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dr. Suman Pant, MD/MBBS
- Phone Number: 0977-14254220
- Email: suman.p@fph.tu.ac.th
Study Contact Backup
- Name: Dr. Bikal Shrestha, MD/MBBS
- Phone Number: 0977-984-1262421
- Email: bikalshrestha@naihs.edu.np
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults aged 18 years and above.
- Confirmed SARS-CoV-2 infection by PCR/RT-PCR. Patients with positive point of care tests can be randomised but have to be confirmed for SARS-CoV-2 by RT-PCR.
- Presence of symptoms consistent with COVID-19 (e.g. shortness of breath, cough, sputum, muscle aches, headache, fatigue, sore throat, loss or change to sense of smell and/or taste, rhinorrhoea and anorexia).
- WHO 10-point Clinical Progression Scale score of 4 to 5
- Patient requires hospitalisation due to severity of COVID-19 or comorbidities if score 3 on the WHO 10-point Clinical Progression Scale.
- Frailty score of ≤6.
- Patient able to provide informed consent.
- Females of child-bearing potential must be non-lactating, must have a negative pregnancy test at Screening, and must agree to continue using contraception throughout the study and for 4 weeks after study completion.
Exclusion Criteria:
Severe or critical COVID-19, e.g.:
- Respiratory rate ≥ 30 breaths per minute OR
- Heart rate ≥ 125 beats per minute OR
- Respiratory failure, defined as clinical need for high-flow oxygen therapy, non- invasive positive pressure ventilation or endotracheal intubation and mechanical ventilation OR
- Shock, defined as systolic blood pressure <90 mm Hg or diastolic blood pressure <60 mm Hg or requiring vasopressors OR
- Multi-organ dysfunction/failure (WHO Clinical Progression Scale score ≥6)
- Hospitalisation for reasons other than severity of COVID-19 or comorbidities (e.g. social reasons, local policies, isolation/quarantine).
- Active bleeding or high risk for bleeding (e.g. known acute gastrointestinal ulcer).
- History of significant haemorrhage (requiring hospitalisation or transfusion) outside of a surgical setting within the last 24 months.
- Familial bleeding diathesis.
- Glucose-6-phosphate dehydrogenase deficiency.
- Severe hepatic and renal impairment as no safety and PK data of isoquercetin are available in these populations.
- Current daily use of aspirin (> 81 mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g. ibuprofen > 800 mg daily or equivalent).
- Concomitant use of Cyclosporine, Warfarin (Coumarin), TPA, strong inducer of CYP3A4, or substrate of CYP3A4 with narrow therapeutic index.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to isoquercetin.
- Pregnancy.
- Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with isoquercetin, breastfeeding should be discontinued if the mother is treated with Isoquercetin. These potential risks may also apply to other agents used in this study.
- Known hypersensitivity to Isoquercetin, Quercetin, or to any of the excipients used in the Isoquercetin capsules.
- Patient with history of poor compliance, or current or past psychiatric disease that might interfere with the ability to comply with the study procedures or give informed consent according to the judgment of the investigator or institutionalized by court decision.
- Patient with any condition that the physician judges could be detrimental to patient participating in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control arm
In this arm subjects will receive the hospital COVID-19 standard care
|
Standard care for COVID-19 as per the hospital guidelines
|
Experimental: Isoquercetin arm
In this arm subjects will receive the hospital COVID-19 standard care + Isoquercetin
|
Standard care for COVID-19 as per the hospital guidelines
Daily 1000 mg Isoquercetin as 4 capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease progression, defined as WHO Clinical Progression Scale score of ≥ 6, at any time from day 1 to day 28
Time Frame: From day 1 to day 28
|
From day 1 to day 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease recovery, defined as WHO Progression Scale score of ≤ 2, at day 28
Time Frame: Day 1 through Day 28
|
Day 1 through Day 28
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the WHO Progression Scale score from baseline
Time Frame: Day 1 through Day 28
|
Day 1 through Day 28
|
Changes in daily breathlessness, cough and sputum scale (BCSS) score (including disaggregated scores)
Time Frame: Day 1 through Day 28
|
Day 1 through Day 28
|
Percentage of patients who progress to require mechanical ventilation
Time Frame: Day 1 through Day 28
|
Day 1 through Day 28
|
Percentage of patients admitted to intensive care unit admission
Time Frame: Day 1 through Day 28
|
Day 1 through Day 28
|
Time to recovery
Time Frame: Day 1 through Day 28
|
Day 1 through Day 28
|
Time to hospital discharge
Time Frame: Day 1 through Day 28
|
Day 1 through Day 28
|
Change in National Early Warning Score (NEWS 2) from baseline
Time Frame: Day 1 through Day 28
|
Day 1 through Day 28
|
All-cause mortality
Time Frame: Day 1 through Day 28
|
Day 1 through Day 28
|
QoL (EQ-5D-5L respiratory questionnaire)
Time Frame: Day 1 through Day 28
|
Day 1 through Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 20, 2021
Primary Completion (Anticipated)
May 20, 2021
Study Completion (Anticipated)
August 15, 2021
Study Registration Dates
First Submitted
January 31, 2021
First Submitted That Met QC Criteria
February 1, 2021
First Posted (Actual)
February 2, 2021
Study Record Updates
Last Update Posted (Actual)
February 5, 2021
Last Update Submitted That Met QC Criteria
February 2, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Hospital standard of care for COVID-19
-
Cadila PharnmaceuticalsCouncil of Scientific and Industrial Research, IndiaCompleted
-
Koç UniversityTerminatedCovid19 | Sarcopenia | Intensive Care Unit Acquired WeaknessTurkey
-
Qurient Co., Ltd.TerminatedCOVID-19 Virus InfectionSouth Africa
-
BioTeke USA, LLCCSSi Life SciencesCompleted
-
Indonesia UniversityCompletedCovid19 | AcupunctureIndonesia
-
Abu Dhabi Stem Cells CenterCompletedCoronavirus Disease 2019 (COVID-19)United Arab Emirates
-
The University of Texas Health Science Center,...National Institute on Minority Health and Health Disparities (NIMHD)Completed
-
King Edward Medical UniversityCompleted
-
South African National Blood ServiceUnknownTherapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19COVID-19 | SARS-CoV-2 Infection | Severe Acute Respiratory Syndrome Coronavirus 2South Africa
-
University of CalgaryHealth CanadaActive, not recruiting